UCLA
Los Angeles, California, United States
My name is Julio Sanchez, a T32 Postdoctoral scholar at UCLA within Professor Robert Prins' Laboratory. Efforts in treating GBM with immunotherapies have fallen short in their efficacy. For this reason, a mechanistic understanding of how immunotherapies influence specific immune cell populations is needed. In the Prins lab, we are utilizing clincal samples and pre-clinical models to answer how the timing of aPD-1 checkpoint blockade and dendritic cell vaccination impacts tumor-specific T cell biology and function.
